Our strategy is to develop biologics for medical conditions where there has been no approved or satisfactory therapy. Our lead product, B-701, is a human antibody targeting FGFR3 (fibroblast growth factor receptor 3) being developed as a treatment for metastatic bladder cancer and achondroplasia (dwarfism).